DK1558265T3 - Anvendelse af dropspirenon til behandling af hypertension - Google Patents

Anvendelse af dropspirenon til behandling af hypertension

Info

Publication number
DK1558265T3
DK1558265T3 DK03769738.0T DK03769738T DK1558265T3 DK 1558265 T3 DK1558265 T3 DK 1558265T3 DK 03769738 T DK03769738 T DK 03769738T DK 1558265 T3 DK1558265 T3 DK 1558265T3
Authority
DK
Denmark
Prior art keywords
women
dropspirenone
hypertension
treatment
menopause
Prior art date
Application number
DK03769738.0T
Other languages
English (en)
Inventor
Siegried Meyerhofer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2002/004628 external-priority patent/WO2004041288A1/en
Priority claimed from US10/287,780 external-priority patent/US20040087563A1/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of DK1558265T3 publication Critical patent/DK1558265T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DK03769738.0T 2002-11-05 2003-11-05 Anvendelse af dropspirenon til behandling af hypertension DK1558265T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2002/004628 WO2004041288A1 (en) 2002-11-05 2002-11-05 Hormone replacement therapy with drospirenone
US10/287,780 US20040087563A1 (en) 2002-11-05 2002-11-05 Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
PCT/IB2003/004946 WO2004041289A1 (en) 2002-11-05 2003-11-05 Cardiovascular protection using anti-aldosteronic progestins

Publications (1)

Publication Number Publication Date
DK1558265T3 true DK1558265T3 (da) 2010-03-15

Family

ID=32314003

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03769738.0T DK1558265T3 (da) 2002-11-05 2003-11-05 Anvendelse af dropspirenon til behandling af hypertension

Country Status (9)

Country Link
EP (1) EP1558265B1 (da)
JP (1) JP2006508945A (da)
AT (1) ATE454155T1 (da)
AU (1) AU2003278434A1 (da)
DE (1) DE60330888D1 (da)
DK (1) DK1558265T3 (da)
ES (1) ES2338781T3 (da)
PT (1) PT1558265E (da)
WO (1) WO2004041289A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
NZ549792A (en) * 2004-03-10 2009-12-24 Bayer Schering Pharma Ag Compositions comprising drospirenone molecularly dispersed
DK1669074T3 (da) * 2004-12-01 2010-09-27 Par Pharmaceuticals Inc Anvendelse af megestrolacetat til forbedring af hjertefunktion og behandling af hjerteinsufficiens
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
EP2052724A1 (en) 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
WO2016203011A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible dosage unit containing an estetrol component
WO2016203044A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
PL3701944T3 (pl) 2015-06-18 2022-04-04 Estetra Srl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
ES2288487T3 (es) * 1999-11-09 2008-01-16 Pharmacia Corporation Uso de eplerenona para tratamiento de la restenosis.
KR100747965B1 (ko) * 2000-01-18 2007-08-08 바이엘 쉐링 파마 악티엔게젤샤프트 호르몬 보충 요법용 드로스피렌온
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
EP1368009A2 (en) * 2000-07-27 2003-12-10 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
EP1313485B1 (en) * 2000-08-28 2005-10-12 Pharmacia Corporation Use of an aldosterone receptor antagonist to improve cognitive function
DE10100911A1 (de) * 2001-01-11 2002-08-01 Schering Ag Verfahren zur Hormonersatztherapie und dessen Darreichungsform

Also Published As

Publication number Publication date
EP1558265A1 (en) 2005-08-03
AU2003278434A1 (en) 2004-06-07
EP1558265B1 (en) 2010-01-06
DE60330888D1 (de) 2010-02-25
ATE454155T1 (de) 2010-01-15
JP2006508945A (ja) 2006-03-16
PT1558265E (pt) 2010-03-22
WO2004041289A1 (en) 2004-05-21
ES2338781T3 (es) 2010-05-12

Similar Documents

Publication Publication Date Title
DK1558265T3 (da) Anvendelse af dropspirenon til behandling af hypertension
DE60315964D1 (de) Verbesserung der herstellung von endogenen gonadotropin
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
WO2005097119A3 (en) Pten inhibitors
HUP0003386A2 (hu) CRF antagonisták alkalmazása depresszió, kardiovaszkuláris betegségek kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0303923A2 (hu) Szterin abszorpció inhibitor(ok)kombinációi kardiovaszkuláris szerekkel vaszkuláris kondíciók kezelésére és a kombinációt tartalmazó készítmények
WO2005105107A3 (en) Hormone treatment of multiple sclerosis
ATE277596T1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
DE60128540D1 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
CR8603A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
MX2007005581A (es) Regimen de dosificacion mejorada de temozolomida para el tratamiento de cancer con base en el nivel de o6-metilguanidi-adn metiltransferasa del paciente.
HUP0400548A2 (hu) Belső szemnyomást csökkentő hatóanyag-kombinációk alkalmazása glaukoma kezelésére szolgáló gyógyszerkészítmények előállítására
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
ATE516366T1 (de) Regulierte aptamer-therapeutika
HUP0400553A2 (hu) Gyógyászati készítmények
WO2004026260A3 (en) Prophylactic and therapeutic hiv aptamers
EE200200379A (et) Meetod ja preparaat antihüpertensiivsete ainete suhtes resistentsuse ja sellega seotud haigusseisundite raviks
BR0317095A (pt) Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease
HUP9901505A2 (hu) Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set